Investors sentiment increased to 0.83 in Q4 2018. Its up 0.01, from 0.82 in 2018Q3. It improved, as 60 investors sold ABBV shares while 631 reduced holdings. 129 funds opened positions while 444 raised stakes. 996.27 million shares or 0.22% more from 994.12 million shares in 2018Q3 were reported. Dorsey And Whitney Limited Liability Company holds 0.29% or 17,532 shares in its portfolio. Orleans Cap Mngmt La accumulated 35,382 shares. Tradewinds Cap Management Ltd Company holds 0.09% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 2,002 shares. Capital City Fl has invested 1.14% in AbbVie Inc. (NYSE:ABBV). Callahan Advsr Limited Liability Company holds 11,828 shares or 0.23% of its portfolio. Town And Country National Bank And Tru Dba First Bankers Tru owns 2.08% invested in AbbVie Inc. (NYSE:ABBV) for 86,734 shares. Qs Ltd Llc stated it has 187,774 shares. Amer Grp Inc invested in 1.86% or 4.91 million shares. 2,178 are held by Private Ocean Ltd Liability. 16,619 are held by First State Bank Trust Communication Of Newtown. Amalgamated Natl Bank holds 0.58% or 223,276 shares. Capital Fund holds 0.02% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 28,427 shares. Reliance Trust Company Of Delaware has invested 0.37% in AbbVie Inc. (NYSE:ABBV). Citadel Advsr Ltd Limited Liability Company accumulated 0% or 19,740 shares. First Hawaiian Comml Bank holds 29,712 shares.
Since November 29, 2018, it had 0 buys, and 5 sales for $21.78 million activity. Schumacher Laura J had sold 94,140 shares worth $8.81M on Tuesday, December 4. $1.50M worth of AbbVie Inc. (NYSE:ABBV) was sold by GONZALEZ RICHARD A on Tuesday, December 11. Another trade for 60,000 shares valued at $5.40 million was sold by CHASE WILLIAM J.
Suntrust Banks Inc increased its stake in Abbvie Inc (ABBV) by 5.17% based on its latest 2018Q4 regulatory filing with the SEC. Suntrust Banks Inc bought 48,379 shares as the company’s stock declined 10.66% while stock markets rallied. The institutional investor held 985,034 shares of the major pharmaceuticals company at the end of 2018Q4, valued at $90.81M, up from 936,655 at the end of the previous reported quarter. Suntrust Banks Inc who had been investing in Abbvie Inc for a number of months, seems to be bullish on the $119.98 billion market cap company. The stock increased 1.74% or $1.39 during the last trading session, reaching $81.34. About 12.75 million shares traded or 76.83% up from the average. AbbVie Inc. (NYSE:ABBV) has declined 30.20% since March 17, 2018 and is downtrending. It has underperformed by 34.57% the S&P500.
Suntrust Banks Inc, which manages about $17.39B US Long portfolio, decreased its stake in Citigroup Inc (NYSE:C) by 108,213 shares to 108,737 shares, valued at $5.66M in 2018Q4, according to the filing. It also reduced its holding in Ishares Tr (PFF) by 113,589 shares in the quarter, leaving it with 1.06M shares, and cut its stake in Comcast Corp New (NASDAQ:CMCSA).
More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Seekingalpha.com which released: “AbbVie, Inc. (ABBV) Presents at Barclays Global Healthcare Broker Conference Call – (Transcript) – Seeking Alpha” on March 13, 2019, also Seekingalpha.com with their article: “Bert’s Recent Purchase – AbbVie – Seeking Alpha” published on February 17, 2019, Seekingalpha.com published: “Teva settlement with FTC resolves all litigation – Seeking Alpha” on February 19, 2019. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Seekingalpha.com and their article: “Synlogic progressing IBD partnership with AbbVie – Seeking Alpha” published on March 06, 2019 as well as Fool.com‘s news article titled: “2 Things Investors Are Missing About AbbVie – Motley Fool” with publication date: March 17, 2019.
AbbVie Inc. (NYSE:ABBV) Ratings Coverage
Among 6 analysts covering AbbVie (NYSE:ABBV), 2 have Buy rating, 1 Sell and 3 Hold. Therefore 33% are positive. AbbVie had 8 analyst reports since October 4, 2018 according to SRatingsIntel. UBS reinitiated it with “Neutral” rating and $91 target in Wednesday, January 23 report. The stock has “Buy” rating by Argus Research on Tuesday, November 6. Piper Jaffray maintained the stock with “Hold” rating in Wednesday, March 13 report. The rating was maintained by Piper Jaffray with “Hold” on Thursday, February 21. The stock of AbbVie Inc. (NYSE:ABBV) has “Neutral” rating given on Thursday, January 3 by Bank of America. On Monday, November 5 the stock rating was maintained by BMO Capital Markets with “Underperform”. Bank of America maintained the shares of ABBV in report on Thursday, October 4 with “Buy” rating.